Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the

Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun...

Related Keywords

India , United States , Mumbai , Maharashtra , Washington , America , Sun Pharma , Roger Tung , Abhishek Sharma , Janet Metz , Abhay Gandhi , Justine Koenigsberg , Gaurav Chugh , Concert Pharmaceuticals , Twitter , Sun Pharmaceutical Industries Ltd , Nasdaq , Foliage Merger Sub Inc , Moelis Company , Chestnut Partners Inc , Concert Investor Relations Department , Health Partners , Drug Administration , Davis Polk Wardwell , Sun Pharmaceutical Industries Limited , Exchange Commission , Prnewswire Sun Pharmaceutical Industries Limited Reuters , Sun Pharma Investor Relations Department , Concert Pharmaceuticals Inc , Goodwin Procter , Adds Deuruxolitinib , Potential Best In Class Oral , Alopecia Areata , Autoimmune Dermatological , Global Infrastructure , Provide Broad Access , Global Dermatology Franchise , Late Stage Product , Significant Unmet , Commence Tender Offer , Acquire All Outstanding Shares , Common Stock , Cash Payment , Equity Consideration , Value Right , Certain Time Based Net Sales , Pharmaceutical Industries Limited , North America , New Drug Application , Concert Board , Davis Polk , Chestnut Partners , Sun Pharmaceutical Industries , Foliage Merger Sub , Tender Offer Statement , Recommendation Statement , Investor Relations Department , Tender Offer , Large Cross Sectional Survey Study , Investigational Dermatology , Cosmet Investig , Pharmaceutical Industries ,